Singapore, Sept. 26 -- Fujifilm Biotechnologies has announced the opening of its manufacturing site in Holly Springs, North Carolina, US. The newest addition to Fujifilm Biotechnologies' global network represents one of the largest commercial-scale cell culture biomanufacturing sites in North America.

The first phase of the planned $3.2 billion manufacturing site opens with a capacity of 8 x 20,000 liters (L) mammalian cell culture bioreactors to encompass drug product and drug substance manufacturing, while adding finished goods capabilities in 2026.

The second phase expansion (announced in 2024) will double capacity with an additional 8 x 20,000 L bioreactors for a total of 16 bioreactors.

"Fujifilm's total global investment of over ...